Le Lézard
Classified in: Science and technology, Business, Covid-19 virus
Subjects: EARNINGS, Conference Call, Webcast

Ontrak Announces 2021 Third Quarter Financial Results


Ontrak, Inc. (NASDAQ: OTRK) ("Ontrak" or the "Company"), a leading AI-powered and telehealth-enabled, virtualized healthcare company, today reported its financial results for the third quarter ended September 30, 2021.

Management Commentary

"During the third quarter we made important progress on building out our sales pipeline. We are now in active discussions with three of the larger national health plans in the country, and we are exchanging data and creating financial models for 4 employer organizations and multiple providers. Our confidence in our ability to fast track growth and convert our pipeline is strong, given the overall market dynamics and our new management team. With industry renowned CMO Dr. Robert Accordino engaging with senior clinical decision makers at customers and prospects, our new Chief Customer Officer Mary Lou Osborne from Aetna leading the conversion of our sales pipeline, and newly appointed CIO Arik Hill accelerating our AI-enabled identification, screening and monitoring capabilities, I feel confident that the company is well positioned to return to historical growth rates."

Third Quarter 2021 Financial Results Highlights

Third Quarter 2021 and Recent Operating Highlights

Financial Outlook

The following outlook is based on information available as of the date of this press release and is subject to change in the future. This outlook solely represents existing and planned enrollment launches, and program expansions with current health plan partners.

For the year ending December 31, 2021, the Company provides the following outlook:

2021 revenue of $82-$86 million, reflecting current expectations with our existing health plan customers regarding outreach pool, budget considerations and timing of expansions.

Conference Call & Webcast Details

The Company will host a conference call/webcast today at 4:30 pm ET/1:30 pm PT. Investors, analysts, employees and the general public can access the call by dialing (833) 519-1269 for U.S. participants or (914) 800-3841 for international participants and referencing conference ID #5477522. A live and archived webcast of the event will be available at: https://ontrakhealth.com/investors/presentations-events.

About Ontrak, Inc.

Ontrak, Inc. (f/k/a Catasys, Inc.) is a leading AI and telehealth-enabled healthcare company, whose mission is to help improve the health and save the lives of as many people as possible. Ontrak identifies, engages, activates and provides care pathways to treatment for the most vulnerable members of the behavioral health population who would otherwise fall through the cracks of the healthcare system. We engage individuals with anxiety, depression, substance use disorder and chronic disease through personalized care coaching and customized care pathways that help them receive the treatment and advocacy they need, despite the socio-economic, medical and health system barriers that exacerbate the severity of their comorbid illnesses. The company's integrated intervention platform uses AI, predictive analytics and digital interfaces combined with dozens of care coach engagements to deliver improved member health, better healthcare system utilization, and durable outcomes and savings to healthcare payors.

Learn more at www.ontrakhealth.com

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward looking statements may include for example statements regarding: expectations regarding future revenue reflecting current expectations with our existing health plan customers regarding outreach pool, budget considerations and timing of expansions; the strength of our pipeline; our ability to fast track growth and convert our pipeline; acceleration of our AI-enabled identification, screening, and operational performance; and driving accelerated growth, expansion and performance. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control, which may cause actual results to differ materially from stated expectations. These risk factors include, among others, dependence on key personnel and the ability to recruit, retain and develop a large and diverse workforce; high customer concentration and the ability of our customer to terminate our contracts for convenience; intense competition and substantial regulation in the health care industry; changes in regulations or issuance of new regulations or interpretations; limited operating history; our inability to execute our business plan; increase our revenue and achieve profitability; lower than anticipated eligible members under our contracts; our inability to recognize revenue; lack of outcomes and statistically significant formal research studies; difficulty enrolling new members and maintaining existing members in our programs; the risk that the treatment programs might not be effective; difficulty in developing, exploiting and protecting proprietary technologies; business disruption and related risks resulting from the outbreak of the novel coronavirus 2019; the risks associated with the adequacy of our existing cash resources and our ability to continue as a going concern; our ability to raise additional capital when needed and our liquidity; and risks related to our ability to realize the potential benefits of and to effectively integrate acquisitions. You are urged to consider statements that include the words "may," "will," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plan," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking For a further list and description of the risks and uncertainties we face, please refer to our most recent Securities and Exchange Commission filings which are available on its website at http://www.sec.gov. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Non-GAAP Financial Measures

To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles, or GAAP, the Company has provided in this press release and the quarterly conference call held on the date hereof certain non-GAAP financial measures. The non-GAAP financial measures presented include EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Non-GAAP net loss, and Non-GAAP net loss per common share, which are not U.S. GAAP financial measures, and clarifies and enhances an understanding of our past performance. We believe that the presentation of these financial measures enhances an investor's understanding of our financial performance. We further believe that these financial measures are useful financial metrics to assess our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business.

EBITDA consists of net loss before interest, taxes, depreciation and amortization expenses. Adjusted EBITDA consists of net loss before interest, taxes, depreciation, amortization, stock-based compensation, reduction in workforce costs, acquisition related costs, and (gain) loss on change in fair value of warrant liability and contingent liability. We believe that making such adjustments provides investors meaningful information to understand our results of operations and the ability to analyze our financial and business trends on a period-to-period basis.

Non-GAAP net loss consists of net loss adjusted for stock-based compensation, acquisition related costs, (gain) loss on change in fair value of warrant liability and contingent liability, gain on forgiveness of PPP loan, and write-off of debt issuance costs. Non-GAAP net loss per common share consists of loss per share adjusted for non-GAAP net loss attributable to common stockholders. We believe that making such adjustments provides investors meaningful information to understand our results of operations and the ability to analyze our financial and business trends on a period-to-period basis.

We believe the above non-GAAP financial measures are commonly used by investors to evaluate our performance and that of our competitors. However, our use of the term EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Non-GAAP net loss and Non-GAAP net loss per common share may vary from that of others in our industry. Neither EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Non-GAAP net loss nor Non-GAAP net loss per common share should be considered as an alternative to net loss before taxes, net loss, net loss per common share or any other performance measures derived in accordance with U.S. GAAP as measures of performance.

ONTRAK, INC.

Consolidated Statements of Operations

(in thousands, except per share data)

(unaudited)

 

 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Revenue

$

18,594

 

 

 

$

24,022

 

 

 

$

73,801

 

 

 

$

53,586

 

 

Cost of revenue

5,856

 

 

 

13,068

 

 

 

27,125

 

 

 

30,177

 

 

Gross profit

12,738

 

 

 

10,954

 

 

 

46,676

 

 

 

23,409

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

Research and development

4,563

 

 

 

3,697

 

 

 

13,531

 

 

 

8,015

 

 

Sales and marketing

2,269

 

 

 

1,165

 

 

 

7,839

 

 

 

3,102

 

 

General and administrative

11,374

 

 

 

9,100

 

 

 

35,305

 

 

 

25,391

 

 

Total operating expenses

18,206

 

 

 

13,962

 

 

 

56,675

 

 

 

36,508

 

 

Operating loss

(5,468

)

 

 

(3,008

)

 

 

(9,999

)

 

 

(13,099

)

 

 

 

 

 

 

 

 

 

Other expense, net

(361

)

 

 

(847

)

 

 

(1,004

)

 

 

(1,226

)

 

Interest expense, net

(2,054

)

 

 

(1,818

)

 

 

(6,090

)

 

 

(5,156

)

 

Net loss

$

(7,883

)

 

 

$

(5,673

)

 

 

$

(17,093

)

 

 

$

(19,481

)

 

Dividends on preferred stock - declared and undeclared

(2,239

)

 

 

(464

)

 

 

(6,716

)

 

 

(464

)

 

Net loss attributable to common stockholders

$

(10,122

)

 

 

$

(6,137

)

 

 

$

(23,809

)

 

 

$

(19,945

)

 

 

 

 

 

 

 

 

 

Net loss per common share, basic and diluted

$

(0.54

)

 

 

$

(0.36

)

 

 

$

(1.31

)

 

 

$

(1.17

)

 

 

 

 

 

 

 

 

 

Weighted-average common shares outstanding, basic and diluted

18,915

 

 

 

17,280

 

 

 

18,236

 

 

 

16,990

 

 

ONTRAK, INC.

Consolidated Balance Sheets

(in thousands, except share and per share data)

 

 

September 30,

 

December 31,

 

2021

 

 

2020

 

Assets

(unaudited)

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

75,303

 

 

 

$

86,907

 

 

Restricted cash - current

8,954

 

 

 

9,127

 

 

Receivables, net

5,203

 

 

 

16,682

 

 

Unbilled receivables

5,260

 

 

 

4,426

 

 

Deferred costs - current

1,207

 

 

 

2,352

 

 

Prepaid expenses and other current assets

2,734

 

 

 

4,144

 

 

Total current assets

98,661

 

 

 

123,638

 

 

Long-term assets:

 

 

 

Property and equipment, net

5,474

 

 

 

2,273

 

 

Restricted cash - long-term

510

 

 

 

7,176

 

 

Goodwill

5,713

 

 

 

5,727

 

 

Intangible assets, net

2,651

 

 

 

3,561

 

 

Other assets

1,120

 

 

 

367

 

 

Operating lease right-of-use assets

1,692

 

 

 

1,959

 

 

Total assets

$

115,821

 

 

 

$

144,701

 

 

 

 

 

 

Liabilities and stockholders' equity

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

1,135

 

 

 

$

1,287

 

 

Accrued compensation and benefits

3,623

 

 

 

4,723

 

 

Deferred revenue

5,321

 

 

 

20,954

 

 

Current portion of operating lease liabilities

546

 

 

 

434

 

 

Other accrued liabilities

5,270

 

 

 

9,012

 

 

Total current liabilities

15,895

 

 

 

36,410

 

 

Long-term liabilities:

 

 

 

Long-term debt, net

46,353

 

 

 

45,719

 

 

Long-term operating lease liabilities

1,082

 

 

 

1,403

 

 

Long-term finance lease liabilities

192

 

 

 

418

 

 

Total liabilities

63,522

 

 

 

83,950

 

 

Commitments and contingencies

 

 

 

 

 

 

 

Stockholders' equity:

 

 

 

Preferred stock, $0.0001 par value; 50,000,000 shares authorized; 3,770,265 shares issued and outstanding at each of September 30, 2021 and December 31, 2020

?

 

 

 

?

 

 

Common stock, $0.0001 par value, 500,000,000 shares authorized; 19,155,481 and

17,543,218 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively

2

 

 

 

2

 

 

Additional paid-in capital

423,414

 

 

 

414,773

 

 

Accumulated deficit

(371,117

)

 

 

(354,024

)

 

Total stockholders' equity

52,299

 

 

 

60,751

 

 

Total liabilities and stockholders' equity

$

115,821

 

 

 

$

144,701

 

 

 

 

 

 

ONTRAK, INC.

Consolidated Statements of Cash Flows

(in thousands, unaudited)

 

 

For the Nine Months Ended
September 30,

 

2021

 

 

2020

 

Cash flows from operating activities

 

 

 

Net loss

$

(17,093

)

 

 

$

(19,481

)

 

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

Stock-based compensation expense

8,871

 

 

 

5,799

 

 

Paid-in-kind interest expense

?

 

 

 

3,500

 

 

Depreciation expense

658

 

 

 

178

 

 

Amortization expense

2,181

 

 

 

1,091

 

 

Gain on forgiveness of PPP loan

(171

)

 

 

?

 

 

Change in fair value of warrants

?

 

 

 

1,217

 

 

Change in fair value of contingent consideration

1,305

 

 

 

?

 

 

401(k) employer match in common shares

860

 

 

 

405

 

 

Changes in operating assets and liabilities:

 

 

 

Receivables

11,478

 

 

 

(597

)

 

Unbilled receivables

(834

)

 

 

(2,238

)

 

Prepaid expenses and other current assets

1,674

 

 

 

(2,260

)

 

Accounts payable

(285

)

 

 

55

 

 

Deferred revenue

(15,633

)

 

 

4,641

 

 

Leases liabilities

(208

)

 

 

(273

)

 

Other accrued liabilities

(3,914

)

 

 

1,879

 

 

Net cash used in operating activities

(11,111

)

 

 

(6,084

)

 

 

 

 

 

Cash flows from investing activities

 

 

 

Purchase of property and equipment

(3,865

)

 

 

(1,131

)

 

Net cash used in investing activities

(3,865

)

 

 

(1,131

)

 

 

 

 

 

Cash flows from financing activities

 

 

 

Proceeds from issuance of preferred stock

?

 

 

 

45,530

 

 

Preferred stock issuance costs

?

 

 

 

(426

)

 

Dividends paid

(6,712

)

 

 

?

 

 

Proceeds from 2024 Notes

?

 

 

 

10,000

 

 

Debt issuance costs

?

 

 

 

(128

)

 

Proceeds from warrant exercise

58

 

 

 

133

 

 

Proceeds from options exercise

5,584

 

 

 

5,742

 

 

Finance lease obligations

(243

)

 

 

(126

)

 

Financed insurance premium payments

(2,154

)

 

 

(131

)

 

Net cash (used in) provided by financing activities

(3,467

)

 

 

60,594

 

 

Net change in cash and restricted cash

(18,443

)

 

 

53,379

 

 

Cash and restricted cash at beginning of period

103,210

 

 

 

14,018

 

 

Cash and restricted cash at end of period

$

84,767

 

 

 

$

67,397

 

 

 

 

 

 

Supplemental disclosure of cash flow information:

 

 

 

Interest paid

$

5,483

 

 

 

$

1,108

 

 

Non cash financing and investing activities:

 

 

 

Reclassification of warrant liability to equity upon exercise of warrant

$

?

 

 

 

$

1,337

 

 

Finance lease and accrued purchases of property and equipment

230

 

 

 

517

 

 

Stock options exercise in transit

?

 

 

 

?

 

 

Financed insurance premiums

?

 

 

 

318

 

 

ONTRAK, INC.

Reconciliation of Non-GAAP Measures

(in thousands, except per share data)

Reconciliation of Operating Loss to EBITDA and Adjusted EBITDA

 

 

 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Operating loss

 

$

(5,468

)

 

 

$

(3,008

)

 

 

$

(9,999

)

 

 

$

(13,099

)

 

Depreciation expense

 

276

 

 

 

96

 

 

 

658

 

 

 

178

 

 

Amortization expense (1)

 

525

 

 

 

178

 

 

 

1,547

 

 

 

482

 

 

EBITDA

 

(4,667

)

 

 

(2,734

)

 

 

(7,794

)

 

 

(12,439

)

 

Stock-based compensation expense

 

2,910

 

 

 

1,751

 

 

 

8,871

 

 

 

5,799

 

 

Restructuring costs (2)

 

49

 

 

 

?

 

 

 

1,339

 

 

 

?

 

 

Acquisition related costs (3)

 

?

 

 

 

176

 

 

 

583

 

 

 

176

 

 

Adjusted EBITDA

 

$

(1,708

)

 

 

$

(807

)

 

 

$

2,999

 

 

 

$

(6,464

)

 

Adjusted EBITDA Margin

 

(9

)%

 

(3

)%

 

4

%

 

(12

)%

Reconciliation of Net Loss to Non-GAAP Net Loss; and Net Loss per Common Share to Non-GAAP Net Loss per Common Share

 

 

 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

 

 

2021

 

2020

 

2021

 

2020

Net loss

 

$

(7,883

)

 

 

$

(5,673

)

 

 

$

(17,093

)

 

 

$

(19,481

)

 

Stock-based compensation expense

 

2,910

 

 

 

1,751

 

 

 

8,871

 

 

 

5,799

 

 

Restructuring costs (2)

 

49

 

 

 

?

 

 

 

1,339

 

 

 

?

 

 

Loss (gain) on change in fair value of warrant liability

 

?

 

 

 

838

 

 

 

(29

)

 

 

1,217

 

 

Loss on change in fair value of contingent liability (4)

 

470

 

 

 

?

 

 

 

1,305

 

 

 

?

 

 

Acquisition related costs (3)

 

?

 

 

 

176

 

 

 

583

 

 

 

176

 

 

Gain on forgiveness of PPP loan (5)

 

?

 

 

 

?

 

 

 

(171

)

 

 

?

 

 

Non-GAAP net loss

 

(4,454

)

 

 

(2,908

)

 

 

(5,195

)

 

 

(12,289

)

 

Dividends on preferred stock - declared and undeclared

 

(2,239

)

 

 

(464

)

 

 

(6,716

)

 

 

(464

)

 

Non-GAAP net loss attributable to common stockholders

 

$

(6,693

)

 

 

$

(3,372

)

 

 

$

(11,911

)

 

 

$

(12,753

)

 

 

 

 

 

 

 

 

 

 

Net loss per common share - basic and diluted

 

$

(0.54

)

 

 

$

(0.36

)

 

 

$

(1.31

)

 

 

$

(1.17

)

 

Non-GAAP net loss per common share - basic and diluted

 

(0.35

)

 

 

(0.20

)

 

 

(0.65

)

 

 

(0.75

)

 

Weighted-average common shares outstanding - basic and diluted

 

18,915

 

 

 

17,280

 

 

 

18,236

 

 

 

16,990

 

 

_______________________

(1)

Relates to operating and financing ROU assets and acquired intangible assets.

(2)

Includes one-time severance and related benefit costs.

(3)

Includes external legal, accounting, and advisory costs associated with acquisition activity.

(4)

Relates to loss resulting from change in fair value of contingent liability related to a stock price guarantee associated with an acquisition.

(5)

Relates to gain recognized upon forgiveness of LifeDojo's PPP loan in May 2021.

 


These press releases may also interest you

at 12:20
The "United States Liquid Biopsy Market Report by Cancer types, Products, Application, Biomarkers, Sample types, End-Users, and Company Analysis 2024-2032" report has been added to ResearchAndMarkets.com's offering. The United States Liquid Biopsy...

at 12:17
Blueprint Prep is proud to announce the groundbreaking release of "Blue," the first and only AI-powered chatbot custom-tailored to help students conquer their nurse practitioner (NP) board preparation....

at 12:15
The Board of Directors of Mullen Group Ltd. ("Mullen Group", "We", "Our" and/or the "Corporation") announced today that it has declared a monthly dividend of $0.06 per Common Share payable to the holders of record of Common Shares at the close of...

at 12:12
Get ready to have your mind expanded and your curiosity ignited as the World Science Festival launches its highly anticipated Spring into Science series of live events in New York City, spanning May 30 - June 2. Take a thrilling journey through the...

at 12:07
TÜV Rheinland, a leading certification, testing and inspection company, presented its annual report in which it highlighted substantial investment in its strategic growth in 2023. The globally active testing group took over ten companies in Germany,...

at 12:05
CData Software, a leading provider of data connectivity solutions, today announced the appointment of Adam DeMichele to the role of Chief Revenue Officer, along with two additions to its GTM leadership team. The new GTM hires include Marie Forshaw,...



News published on and distributed by: